
Intellia Therapeutics (NTLA) Stock
Clinical stage biotech company developing gene editing medicines. Here's the price, business snapshot, and what's worth knowing about Intellia Therapeutics in November 2026.
Intellia Therapeutics (NTLA) is a clinical-stage biotechnology company developing CRISPR/Cas9-based gene‑editing therapies. It is pursuing both in vivo and ex vivo approaches targeting genetic and liver diseases, with a pipeline of early clinical and preclinical programmes. Investors should understand that Intellia’s potential rests on demonstrating safe, durable benefits in human trials — a process that can take years and is subject to clinical, regulatory and competitive risk. With a market capitalisation near $2.9bn, the company’s valuation is sensitive to trial readouts, partnership deals and financing activity. Research and development spending is substantial and outcomes are uncertain, so share price volatility is common. This summary is educational only and not personalised financial advice; investors should consider their time horizon, risk tolerance and diversification needs before considering exposure to NTLA.
Intellia Therapeutics (NTLA) Stock Forecast
Analyst price target, next 12 months
$39.26
+292.6% vs today's $10.00
Price range over the last 12 months
Close to its 12-month low
Analysts covering Intellia Therapeutics have a consensus 12-month target of $39.26, above the current price of $10.00.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping INTELLIA's stock as it may rise towards its target price of $39.26.
Financial Health
Intellia Therapeutics is generating modest revenue and cash flow, indicating a stable but cautious financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
CRISPR Therapy Pipeline
Early clinical readouts could materially affect valuation, though trials can fail and timelines often slip.
Clinical Catalysts Ahead
Trial milestones, regulatory updates and partnerships tend to move the stock; outcomes remain binary and uncertain.
Long‑term Potential
Successful programmes could change care for some diseases, but benefits are speculative and carry substantial scientific and commercial risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.